The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MPN Advances Day 2019 | Myelofibrosis management: ruxolitinib, fedratinib, transplant
Ruben Mesa, MD, FACP, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, provides an update on the management of myelofibrosis in 2019. He highlights fedratinib, which was recently approved in the US and may be making its way to Europe, as well as stem cell transplantation. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.
